Divi's Laboratories fell 10.63% to Rs 774 at 12:25 IST on BSE, extending Friday's slump triggered by media reports of adverse observations from the US drug regulator made on its Vizag facility in Andhra Pradesh.
Meanwhile, the BSE Sensex was down 247.61 points, or 0.95%, to 25,793.09.
On the BSE, so far 15.06 lakh shares were traded in the counter, compared with average daily volumes of 60,581 shares in the past one quarter. The stock had hit a high of Rs 855 and a low of Rs 745 so far during the day.
The stock hit a record high of Rs 1,380 on 16 September 2016. The stock hit a 52-week low of Rs 745 on 26 December 2016. The stock had underperformed the market over the past 30 days till 23 December 2016, falling 24.37% compared with the 0.70% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 35.07% as against Sensex's 9.17% decline.
The large-cap company has equity capital of Rs 53.09 crore. Face value per share is Rs 2.
Shares of Divi's Laboratories slumped 21.87% to Rs 866.10 on Friday, 23 December 2016, following media reports of adverse observations from the US Food and Drug Administration (USFDA) made on its Vizag facility in Andhra Pradesh. Divis Laboratories is in the process of replying to the observations raised by USFDA. Due process of reply to these observations requires Divis Laboratories to respond in detail and this is being done in time, the company said in a response to the clarification sought by the stock exchanges on the steep fall. These observations have not impacted the company's operations, the company added. USFDA inspected the Unit-2 plant from 29 November 2016 to 6 December 2016 and issued a Form 483 with five observations pertaining to breaches in data integrity, improper controls and violations of current good manufacturing practices (cGMP). The company issued the clarification after market hours on Friday, 23 December 2016.
The stock has fallen 30.18% in two trading sessions from its close of Rs 1,108.60 on Thursday, 22 December 2016.
More From This Section
Divi's Laboratories' net profit fell 24.6% to Rs 223.85 crore on 3.11% growth in net sales to Rs 991.82 crore in Q2 September 2016 over Q2 September 2015.
Divi's Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics, custom synthesis of API's and advanced intermediates for discovery compounds for pharma giants, building blocks for peptides, building blocks for nucleotides, carotenoids and chiral ligands.
Powered by Capital Market - Live News